Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
NEW YORK, May 01, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results prior to market open on Tuesday, May 8, 2018. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. Eastern Time to discuss the results.
Intercept management will also be presenting at the following upcoming investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference at 9:20 a.m. ET on Wednesday, May 9, 2018
- Bank of America Merrill Lynch 2018 Healthcare Conference at 5:00 p.m. PT on Tuesday, May 15, 2018
- UBS Global Healthcare Conference at 3:00 p.m. ET on Monday, May 21, 2018
- Jefferies 2018 Global Healthcare Conference at 9:00 a.m. ET on Friday, June 8, 2018
Webcast information for these events will be available on the investor page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
CONTACT
For more information about Intercept Pharmaceuticals, please contact:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
